FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula:
or a pharmaceutically acceptable salt thereof; or to N-methyl-(D)-glucamine salt of formula:
.
EFFECT: compounds are useful in treatment of inflammatory bowel disease.
6 cl, 21 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF S-NITROZOGLUTATION-REDUCTASE INHIBITORS | 2011 |
|
RU2599144C2 |
| MEDICINAL PRODUCTS BASED ON LANTHIONINE SYNTHETASE C-LIKE 2 PROTEIN | 2020 |
|
RU2768888C1 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2018 |
|
RU2837261C2 |
| MEDICINES BASED ON LANTIONINE SYNTHETASE OF C-LIKE PROTEIN 2 | 2015 |
|
RU2741576C2 |
| BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2597364C2 |
| PYRIMIDINE DERIVATIVES - INHIBITORS OF REPRODUCTION OF VIRUSES RELATED TO GENUS ORTHOFLAVIVIRUS | 2023 |
|
RU2831118C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA | 2013 |
|
RU2657797C2 |
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
| BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
| SPIRO COMPOUNDS AS ERK INHIBITORS AND THEIR USE | 2020 |
|
RU2800042C1 |
